Compare Globus Medical Inc. Class A Common Stock (GMED) vs Ross Stores, Inc. (ROST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Globus Medical Inc. Class A Common Stock vs Ross Stores, Inc. — how do they compare? Globus Medical Inc. Class A Common Stock trades at $76.99 (market cap $10.25B), while Ross Stores, Inc. trades at $232.31 (market cap $73.66B). The key difference: Ross Stores, Inc. is far larger — about 7.2× Globus Medical Inc. Class A Common Stock's market cap, and Ross Stores, Inc. pays a 0.77% dividend while Globus Medical Inc. Class A Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Globus Medical Inc. Class A Common Stock for 0 Days and Ross Stores, Inc. for 48 Days on average.
| GMED | ROST | |
|---|---|---|
Market Cap | $10.25B | $73.66B |
Volume | 1,059,528 | 1,784,732 |
Sector | Health | Consumer Cyclical |
52-Week High | $96.82 | $255.23 |
52-Week Low | $58.33 | $155.21 |
Typical Hold Time | 0 Days | 48 Days |
Enterprise Value | $9.76B | $74.11B |
Dividend Yield | — | 0.77% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Globus Medical (GMED) trades at $76.32, showing minimal daily movement with a 0.1% gain. The stock demonstrates strong fundamental performance with consistent earnings beats in recent quarters and robust profitability metrics including 68.55% gross margins and 17.03% net income margins. Technical indicators suggest neutral positioning near key support at $73 with resistance at $74. Recent developments include new product showcases at industry conferences and upcoming Q3 earnings release.
GMED presents a compelling investment case with strong analyst support (72% buy rating) and 25% upside to consensus target of $95.13. The company maintains solid revenue growth trajectory and debt-free balance sheet, though investors should monitor competitive pressures in medical devices and potential margin compression as revenue scales. Near-term catalysts include Q3 earnings results expected November 5, 2026.
Ross Stores (ROST) trades at $225.68, down slightly by 0.07% on the day, with a bearish technical signal despite strong fundamental performance. The company has consistently beaten earnings expectations in recent quarters, with Q2 2026 EPS of $2.66 exceeding the $1.95 estimate. Revenue growth continues with $21.13B in 2025, supported by store expansion initiatives and value-focused strategies that are attracting cost-conscious shoppers.
ROST presents a compelling investment case with 64% analyst buy ratings and a $274.14 consensus price target representing 22% upside potential. However, near-term technical weakness and competitive pressures in discount retail warrant caution. The stock's premium valuation at 27.29 P/E requires sustained earnings growth to justify current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Globus Medical Inc. Class A Common Stock
Globus Medical, Inc. develops and manufactures medical devices for treating musculoskeletal disorders, including spine, orthopedic trauma, and neurosurgical products. It operates in US and internationally, serving surgeons and healthcare providers.
Read more on GMED →About Ross Stores, Inc.
Ross Stores is a leading American off-price apparel and home fashion retailer, operating over 1,920 stores (at the end of fiscal 2021) across the Ross Dress for Less and dd's Discounts banners. Ross offers a variety of name-brand products and targets undercutting conventional retailers' regular prices by 20%-70%. The company uses an opportunistic, flexible merchandising approach
Read more on ROST →
